MCG is secondary only to a coronary
angiogram . . . in terms of its prognostic ability.||
Premier Heart's MCG technology has earned the respect and support of
many leading figures in the medical community, including Mr. Peter Nichols,
current chairman of the board of Boston Scientific Corporation and Dr.
Eberhard Grube, chief of cardiology and angiology at the Siegburg Heart Center
Some of our clients and supporters have been kind enough to offer
their views on the clinical utility and future potential of the MCG
technology, a selection of which have been reproduced below.
For additional information you may
contact us, or
contact one of our clients.
Dr. Charles K. Micelli, M.D., F.A.C.P., F.A.A.C., F.C.C.P.
Dr. Micelli has been using Premier Heart's MCG technology since early
2008, and has incorporated it into his daily practice as a major tool
for the detection of coronary artery disease. He has praised the MCG
system as "an invaluable tool which is on the cutting edge of
technology", seeing MCG as "a major breakthrough that will
Dr. Micelli's reference letter
Dr. Franz Ritucci, M.D.
Dr. Ritucci is a front-line physician specializing in Urgent Care
and Emergency Medicine. His team has been using the MCG system since
January of 2008, and has been a strong advocate of its use in the
Emergency and Urgent Care settings.
Dr. Ritucci has noted that MCG "is able to identify patients . . . with
significant coronary stenosis" in cases where traditional diagnostic
modalities, with the MCG diagnosis subsequently validated through
cardiac catheterization. Additionally, he has praised the high
negative predictive value of the MCG system, "which is beneficial
in preventing patients with an abnormal or equivocal stress test
from having to undergo costly catheterization".
Dr. Howard L. Sacher, M.D.
Dr. Sacher and his colleagues began using the MCG system in mid-2008
as part of their suite of tools for diagnosing coronary artery
disease. They have found the MCG results to correlate with their
expectations based on clinical indicators and risk factors.
Dr. Sacher's Reference Letter
Dr. H. Robert Silverstein, M.D., F.A.C.C.
Dr. Silverstein was one of Premier Heart's earliest clinical users,
and has been using our MCG system for seven years. In his appraisal of
the MCG system Dr. Silverstein noted that "it is the uncanny ability
of the MCG EKG to reveal safety as well as danger", noting that in
his experience our technology is "secondary only to a coronary
Dr. Silverstein's Reference Letter
Dr. John E. Strobeck, M.D., Ph.D.
Dr. Strobeck is the founder and medical director of Heart-Lung
Associates of America, one of America's leading cardiac care
specialty groups. He has been uing Premier Heart's technology
in his practice since February of 2008, and has
been an outspoken advocate of the benefits of the MCG technology for
both detecting and ruling out coronary artery disease.
Dr. Strobeck "was astounded by the accuracy with which [MCG]
was able to identify patients . . . with significant coronary
stenosis", particularly in cases where other conventional diagnostic
tools produced negative results. He has also praised the ability
of MCG analysis to detect conditions in patients with normal results
from traditional diagnostic tools.
Dr. Strobeck's Reference Letter
Dr. Wilbert Aronow, M.D., F.A.C.C.
Division of Cardiology, Westchester Medical Center, NY
Dr. Aronow is a Professor of Medicine at New York Medical College and
head of teaching and clinical cardiology at Westchester Medical Center.
He is also a reknowned researcher and editor of many peer-reviewed
Dr. Arronow revewed the data from Premier Heart's first clinical trial
at Westchester Medical Center.
Dr. Eberhard Grube, M.D.
Chair of Dept. of Cardiology, Siegburg Heart Center, Germany
Dr. Grube is Chief of the Department of Cardiology and Angiology at
the Siegburg Heart Center, as well as a Consulting Professor of
Medicine at Stanford University. He is internationally reknowned as
an innovator in the development and testing of new devices and
procedures in cardiology, and has taken the lead in cliical testing
of drug-eluting stents, percutaneous closure devices and catheter-based
Dr. Grube was the principal investigator of Premier Heart's clinical
trials at the Siegburg heart center, and co-authored several articles
discussing the results of that trials.
Dr. Michael Imhoff, M.D., Ph.D.
Dept. for Medical Informatics, Biometrics & Epidemiology, Ruhr University, Germany
Dr. Imhoff is a board certified surgeon and intensivist with 18 years
clinical practice in one of the largest hospitals in Europe. He also
holds a Ph.D. in Medical Informatics and Statistics, and serves as
a strategic consultant to Dräger Medical and Siemens Medical.
His research covers substantial portions of the medical field including
surgical intensive care medicine, patient monitoring and clinical data
management, statistical analisys of patient and trial data, and
the application of artificial intelligence in medicine.
Dr. Imhoff has performed an extensive analysis of Premier Heart's
clinical trial data in his capacity as a consultant to Dräger
Medical and Siemens Medical, and has co-authored several articles
analyzing the clinical efficacy of the MCG technology.
Dr. Kotaro Obunai, M.D.
Dept. of Cardiology, New York Presbyterian Hospital-Columbia University Med. Center
Dr. Obunai has reviewed data from Premier Heart's clinical trial meta
analysis, summarizing results and trends across our clinical trials
through 2008. He has praised the resuts of MCG testing, noting that
it has "the highest accuracy result I've ever seen ... with
non-invasive testing", especially noting its high accuracy in women.
Dr. Obunai's email
Dr. Kazuko Tajiri, M.D., Ph.D.
Dept. of Cardiovascular & Internal Med. — Tsukuba University, Japan.
Dr. Tajiri is one of several cardiologists and internists who reviewed
Premier Heart's data during our initial research into the Asia-Pacific
market. Among other comments, Dr. Tajiri noted that the MCG system
was "ground-breaking", describing it as "a useful tool for the
diagnosis of ischemic heart disease" and praising both its current
results and future potential.